Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Horizon (HZNP) To Buy Global Rights To Actimmune, Stock Down

Published 05/19/2016, 09:10 PM
Updated 07/09/2023, 06:31 AM
BMY
-
HZNP
-
ANIP
-
TVTX
-

Horizon Pharma plc (NASDAQ:HZNP) announced that its affiliate has entered into a definitive agreement under which it will acquire the worldwide rights to interferon gamma-1b from Boehringer Ingelheim International GmbH. Interferon gamma-1b is commercialized by Boehringer Ingelheim in an estimated 30 countries primarily in Europe and the Middle East under the trade names Imukin, Imukine, Immukin and Immukine.

Per the agreement terms, Horizon Pharma paid €5 million to Boehringer Ingelheim upon signing and will pay €20 million upon closing for the rights to interferon gamma-1b in all territories outside the U.S, Canada and Japan. The transaction is expected to close by the end of 2016.

We note that Horizon Pharma currently owns the rights to interferon gamma-1b, which is marketed by the company in the U.S., Canada, and Japan, under the trade name Actimmune.

Horizon Pharma said that it will immediately start investing in related manufacturing, supply chain, regulatory and commercial activities for interferon gamma-1b. Owing to this, the company now expects a reduction of approximately $10 million from the prior 2016 EBITDA guidance. The company had earlier guided 2016 adjusted EBITDA in the range of $505 million to $520 million.

Meanwhile, Horizon Pharma has licensed the U.S., European and Canadian intellectual property rights to interferon gamma-1b for the treatment of Friedreich's ataxia under the terms of a separate agreement with an undisclosed third party.

We note that Actimmune is the only FDA-approved treatment for chronic granulomatous disease and severe, malignant osteopetrosis. Horizon Pharma is currently working on expanding the drug’s label further. Earlier this month, patient enrolment in a randomized, double-blind, placebo-controlled phase III study (STEADFAST) on Actimmune for the treatment of Friedreich's ataxia was completed. Top-line data is anticipated by the end of 2016.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Actimmune is also being evaluated in combination with a PD-1 checkpoint inhibitor, Bristol-Myers Squibb Company’s (NYSE:BMY) Opdivo, in an investigator-initiated phase I study for the treatment of both kidney and bladder cancer.

Horizon Pharma’s shares were down 4.7% following the announcement. Nevertheless, we are pleased with the company acquiring global rights to Actimmune. Moreover, label expansion of the drug will boost its commercial potential further.

Horizon Pharma is currently a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) and Retrophin, Inc. (NASDAQ:RTRX) , each sporting a Zacks Rank #1 (Strong Buy).



BRISTOL-MYERS (BMY): Free Stock Analysis Report

RETROPHIN INC (RTRX): Free Stock Analysis Report

HORIZON PHARMA (HZNP): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.